Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 21 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Fundamental Analysis of Glaxosmithkline Pharmaceuticals Ltd

About the Company - Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3217.51 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsGSK House, Dr. Annie Besant Road, Mumbai Maharashtra 400030in.investorquery@gsk.com
http://www.gsk-india.com
Management
NamePosition Held
Ms. R S KarnadChairperson
Mr. B AkshikarManaging Director
Mr. J ChandyWholeTime Director & CFO
Mr. S WilliamsNon Executive Director
Mr. M AnandIndependent Director
Dr.(Ms.) S MaheshwariIndependent Director
Mr. A N RoyIndependent Director
Mr. D SundaramIndependent Director
Mr. P V BhideIndependent Director

Basic Stock Data of Glaxosmithkline Pharmaceuticals Ltd

Last Updated: July 20, 2024, 11:07 pm

Market Cap 43,591 Cr.
Current Price 2,573
High / Low2,760/1,380
Stock P/E66.4
Book Value 105
Dividend Yield1.24 %
ROCE51.3 %
ROE37.3 %
Face Value 10.0
PEG Ratio1.40

Data Source: screener.in

Competitors of Glaxosmithkline Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Panacea Biotec Ltd 806 Cr. 132202/112 1370.00 %3.60 %4.10 % 1.00
Themis Medicare Ltd 2,002 Cr. 218266/13747.5 41.00.23 %13.5 %11.8 % 1.00
Cipla Ltd 1,19,957 Cr. 1,4861,582/1,03828.2 3310.88 %23.1 %17.0 % 2.00
Laurus Labs Ltd 23,745 Cr. 440485/328106 78.10.45 %7.50 %5.43 % 2.00
Orchid Pharma Ltd 6,584 Cr. 1,2981,360/43271.4 2310.00 %9.32 %9.92 % 10.0
Industry Average16,402.73 Cr1,276.6743.71209.970.35%16.83%16.18%6.44

Glaxosmithkline Pharmaceuticals Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales879792744718934816810745917802787762957
Expenses674611588586678618634596660574618618668
Operating Profit205181157133256198175149257229170144289
OPM %23%23%21%18%27%24%22%20%28%29%22%19%30%
Other Income-5542-79463041,322312212385428
Interest1111010100100
Depreciation22181818171815161616171618
Profit before tax127204601602681841,482163262224190181299
Tax %40%23%76%24%24%18%18%27%26%27%30%27%27%
Net Profit76157141212041501,219119193165133132218
EPS in Rs4.519.240.857.1512.068.8871.967.0411.429.717.887.8112.84

Last Updated: July 10, 2024, 5:20 pm

Glaxosmithkline Pharmaceuticals Ltd Quarterly Chart

Glaxosmithkline Pharmaceuticals Ltd Profit & Loss

Last Updated: July 10, 2024, 5:20 pm

MonthDec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales2,4142,6472,5633,3052,8382,9082,8713,1283,2242,9263,2783,2523,308
Expenses1,6121,8242,0342,6722,3602,4892,3632,5272,5672,3272,5162,4472,477
Operating Profit802822528633478420508601657598762804832
OPM %33%31%21%19%17%14%18%19%20%20%23%25%25%
Other Income-1773020314912511970131-26291,401103132
Interest0000000164221
Depreciation20182025252738498379686668
Profit before tax6058347117565785115406833065252,093839894
Tax %29%33%32%37%35%34%35%35%70%32%19%27%
Net Profit429562482476376337351445933581,695611648
EPS in Rs25.3033.1728.4328.1222.2019.8820.7026.295.5021.14100.0436.0538.24
Dividend Payout %89%75%88%111%113%75%85%76%727%142%90%89%

Glaxosmithkline Pharmaceuticals Ltd Profit & Loss Yearly Chart

Glaxosmithkline Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:3%
5 Years:2%
3 Years:6%
TTM:6%
Compounded Profit Growth
10 Years:4%
5 Years:9%
3 Years:11%
TTM:11%
Stock Price CAGR
10 Years:8%
5 Years:17%
3 Years:17%
1 Year:83%
Return on Equity
10 Years:28%
5 Years:37%
3 Years:49%
Last Year:37%

Last Updated: July 17, 2024, 5:41 pm

Glaxosmithkline Pharmaceuticals Ltd Balance Sheet

Last Updated: July 10, 2024, 5:20 pm

MonthDec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital85858585858585169169169169169169
Reserves1,8511,9221,9051,7442,0991,9221,9731,9701,6511,3092,4941,5721,370
Borrowings55432211035201621
Other Liabilities1,0891,0771,1361,3848699951,8891,7711,3121,6021,9501,5701,709
Total Liabilities3,0303,0883,1303,2163,0553,0043,9473,9113,1333,1154,6333,3273,270
Fixed Assets9989100123204258325432758387331330318
CWIP1644621152686059231,00312013302026
Investments11255100600000366518514
Other Assets2,8022,9002,9582,9772,5772,1402,7002,4772,2552,7153,9072,4582,412
Total Assets3,0303,0883,1303,2163,0553,0043,9473,9113,1333,1154,6333,3273,270

Glaxosmithkline Pharmaceuticals Ltd Reserves and Borrowings Chart

Glaxosmithkline Pharmaceuticals Ltd Cash Flow

MonthDec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 314281338139234473409490578811484582
Cash from Investing Activity -110189180499301-104-153-57418-4068089
Cash from Financing Activity -441-494-497-638-511-307-358-428-696-524-1,543-562
Net Cash Flow-237-2421-02462-1026300-119-25129

Glaxosmithkline Pharmaceuticals Ltd Financial Efficiency Indicators

MonthDec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days131614111621191411272322
Inventory Days1329410991156111147131135159144131
Days Payable807890749773149109100135156122
Cash Conversion Cycle663233277560173646501131
Working Capital Days-49-42-45-48267-90-72-38-37-92-55
ROCE %48%50%34%42%29%22%26%31%33%38%37%36%

Glaxosmithkline Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Glaxosmithkline Pharmaceuticals Ltd Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
FIIs1.61%1.72%2.04%2.18%2.16%2.17%2.28%2.28%2.41%2.50%2.93%3.48%
DIIs10.93%10.83%10.73%10.73%10.65%10.54%10.29%10.31%10.25%10.01%8.64%7.90%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.01%0.00%
Public12.46%12.45%12.23%12.09%12.19%12.29%12.43%12.43%12.35%12.48%13.42%13.62%
No. of Shareholders1,20,4761,21,4451,23,4801,10,1411,12,9641,16,6511,20,1271,20,4151,19,0321,15,2681,14,6631,18,994

Glaxosmithkline Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Glaxosmithkline Pharmaceuticals Ltd Shareholders

Glaxosmithkline Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Aditya Birla Sun Life ELSS Tax Saver Fund1,218,8721.42201.98806,8952024-07-2051.06%
Nippon India Pharma Fund853,9072.28141.5806,8952024-07-205.83%
ICICI Prudential Large & Mid Cap Fund839,1791.44139.06806,8952024-07-204%
SBI Magnum Midcap Fund806,8950.93133.71806,8952024-07-200%
Aditya Birla Sun Life MNC Fund - Div753,6003.58124.88806,8952024-07-20-6.6%
Aditya Birla Sun Life MNC Fund - Gr753,6003.58124.88806,8952024-07-20-6.6%
ICICI Prudential Multi Asset Fund753,2570.45124.82806,8952024-07-20-6.65%
Nippon India Growth Fund559,0000.4392.63806,8952024-07-20-30.72%
ICICI Prudential Value Discovery Fund355,1840.1758.86806,8952024-07-20-55.98%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund293,8141.4848.69806,8952024-07-20-63.59%

Glaxosmithkline Pharmaceuticals Ltd ROCE Trend

Glaxosmithkline Pharmaceuticals Ltd EPS Trend

Glaxosmithkline Pharmaceuticals Ltd Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)41.1436.0899.2931.355.50
Diluted EPS (Rs.)34.8336.05100.0421.145.50
Cash EPS (Rs.)38.9439.93104.0625.7810.38
Book Value[Excl.RevalReserv]/Share (Rs.)104.93102.79157.1987.26107.47
Book Value[Incl.RevalReserv]/Share (Rs.)104.93102.79157.1987.26107.47
Revenue From Operations / Share (Rs.)203.87191.95193.50172.70190.33
PBDIT / Share (Rs.)60.8753.4249.4541.8443.46
PBIT / Share (Rs.)56.7649.5445.4237.2038.58
PBT / Share (Rs.)48.1849.3745.9926.8018.05
Net Profit / Share (Rs.)34.8236.05100.0421.145.50
NP After MI And SOA / Share (Rs.)34.8236.41100.0421.145.50
PBDIT Margin (%)29.8627.8225.5524.2222.83
PBIT Margin (%)27.8425.8023.4721.5320.26
PBT Margin (%)23.6325.7223.7615.519.48
Net Profit Margin (%)17.0818.7851.6912.242.89
NP After MI And SOA Margin (%)17.0818.9651.6912.242.89
Return on Networth / Equity (%)33.1835.4163.6424.225.11
Return on Capital Employeed (%)47.3341.9526.2135.8030.95
Return On Assets (%)16.5818.5336.5711.492.97
Asset Turnover Ratio (%)1.000.800.830.930.91
Current Ratio (X)1.981.882.181.631.74
Quick Ratio (X)1.631.531.871.221.26
Inventory Turnover Ratio (X)1.110.811.040.890.97
Dividend Payout Ratio (NP) (%)0.00247.2129.98189.20363.51
Dividend Payout Ratio (CP) (%)0.00223.3928.82155.15192.63
Earning Retention Ratio (%)0.00-147.2170.02-89.20-263.51
Cash Earning Retention Ratio (%)0.00-123.3971.18-55.15-92.63
Interest Coverage Ratio (X)572.93499.36419.65200.69116.21
Interest Coverage Ratio (Post Tax) (X)408.54336.84185.96131.2269.61
Enterprise Value (Cr.)31854.8421275.9725686.8623243.3020012.10
EV / Net Operating Revenue (X)9.226.547.847.946.21
EV / EBITDA (X)30.8923.5130.6732.8027.18
MarketCap / Net Operating Revenue (X)9.536.908.598.346.54
Retention Ratios (%)0.00-147.2170.01-89.20-263.51
Price / BV (X)18.5212.8810.5816.5111.59
Price / Net Operating Revenue (X)9.536.908.598.346.54
EarningsYield0.010.020.060.010.00

Glaxosmithkline Pharmaceuticals Ltd Profitability Ratios (%)

Glaxosmithkline Pharmaceuticals Ltd Liquidity Ratios

Glaxosmithkline Pharmaceuticals Ltd Liquidity Ratios (%)

Glaxosmithkline Pharmaceuticals Ltd Interest Coverage Ratios (%)

Glaxosmithkline Pharmaceuticals Ltd Valuation Ratios

Fair Value

Fair Value: 2,632.80

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 2.32% compared to the current price 2573

Intrinsic Value: 3,880.16

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 50.80% compared to the current price 2573

Last 5 Year EPS CAGR: 47.38%

*Investments are subject to market risks

Strength and Weakness of Glaxosmithkline Pharmaceuticals Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 35.50%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -44.58, which is a positive sign.
  3. The company has higher reserves (1,847.42 cr) compared to borrowings (9.00 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (2.46 cr) and profit (598.77 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 40.33, which may not be favorable.

FAQ

What is the latest fair value of Glaxosmithkline Pharmaceuticals Ltd?

The latest fair value of Glaxosmithkline Pharmaceuticals Ltd is ₹2632.80.

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?

The Market Cap of Glaxosmithkline Pharmaceuticals Ltd is 43,591 Cr..

What is the current Stock Price of Glaxosmithkline Pharmaceuticals Ltd as on 21 July 2024?

The current stock price of Glaxosmithkline Pharmaceuticals Ltd as on 21 July 2024 is 2,573.

What is the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks in FY 2024?

In FY 2024, the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks is 2,760/1,380.

What is the Stock P/E of Glaxosmithkline Pharmaceuticals Ltd?

The Stock P/E of Glaxosmithkline Pharmaceuticals Ltd is 66.4.

What is the Book Value of Glaxosmithkline Pharmaceuticals Ltd?

The Book Value of Glaxosmithkline Pharmaceuticals Ltd is 105.

What is the Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd?

The Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd is 1.24 %.

What is the ROCE of Glaxosmithkline Pharmaceuticals Ltd?

The ROCE of Glaxosmithkline Pharmaceuticals Ltd is 51.3 %.

What is the ROE of Glaxosmithkline Pharmaceuticals Ltd?

The ROE of Glaxosmithkline Pharmaceuticals Ltd is 37.3 %.

What is the Face Value of Glaxosmithkline Pharmaceuticals Ltd?

The Face Value of Glaxosmithkline Pharmaceuticals Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Glaxosmithkline Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE